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6ABBREVIATIONS
APGAR - Appearance, Pulse, Grimace, Activity, Respiration
DIC - Disseminated Intravascular Coagulation
HELLP - Hemolysis, Elevated Liver enzymes, Low Platelets
HLA-G - Human Leucocyte Antigen G
IUGR - Intra Uterine Growth Restriction
IUD - Intra Uterine Death
MGA - Maternal Gestational Age
NICU - Neonatal Intensive Care Unit
PLGF - Placental Like Growth factor
PPH - Post Partum Hemorrhage
SAM - S-Adenosyl Methionine
sENG - soluble Endoglin
sFlt-1 - soluble Fms-like tyrosine kinase 1
THFA - Tetra Hydro Folic Acid
VEGF - Vascular Endothelial Growth Factor
7INTRODUCTION
Preeclampsia is a pregnancy specific disorder which complicates
about 3-10% of all nulliparous gestations[1]. The incidence is markedly
influenced by race and ethnicity. Preeclampsia is the most common serious
medical disorder of human pregnancy. It is characterized by the
development of hypertension with  proteinuria after 20 weeks of gestation.
Edema  is often present but is not a requisite for the diagnosis.
Preeclampsia is still regarded as a disease of theories and its etiology has
remained poorly understood. Although the specific cause still remains
unknown, endothelial dysfunction has been considered central in the
pathophysiology of preeclampsia.
Homocysteine is a sulfur containing aminoacid primarily derived
from the demethylation of dietary methionine required for the growth of
cells and tissues in the human body. Hyperhomocysteinemia leads to
endothelial dysfunction through various mechanisms. Homocysteine also
interferes with the fibrinolytic system adding to the pathophysiology of
preeclampsia.
In normal pregnancy homocysteine levels are decreased than the non
pregnant level[2], either due to hemodilution of pregnancy or the relative
deficiency due to increase in requirement by the mother and  fetus.
8Maternal hyperhomocysteinemia has been  associated with a number of
pregnancy related diseases like preeclampsia, placental abruption,
recurrent pregnancy loss, still birth, deep vein thrombosis and neural tube
defects in the newborn[3].
It has been proposed that hyperhomocysteinemia may be associated
with preeclampsia as the homocysteine mediated vascular damages are
similar to those associated with preeclampsia. Though many studies are
done elsewhere, studies on homocysteine in pregnancy are limited in South
India. Also there are limited studies correlating maternal homocysteine
level with the severity of preeclampsia and with the maternal and fetal
outcomes of preeclamptic mothers.
This study is mainly aimed to find the association between maternal
homocysteine levels and preeclampsia and its severity and the  correlation
of maternal homocysteine level  with maternal and fetal outcome of
preeclamptic mothers .
9AIMS AND OBJECTIVES OF THE STUDY
 To study the association of homocysteine levels among normal, mild
and severe preeclamptic pregnant women.
 To study the association between the maternal homocysteine levels
and the severity of preeclampsia.
 Maternal outcome including maternal morbidities due to the various
complications of preeclampsia are to be studied for any association
with the homocysteine level.
 Foetal outcome like term/preterm , IUD, IUGR, neonatal mortality,
birth weight ,APGAR score, duration of NICU stay are correlated
with the maternal homocysteine level to find out any significant
association.
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REVIEW OF LITERATURE
PREECLAMPSIA
Preeclampsia is a  pregnancy specific syndrome which is
characterized by variable degrees of placental dysfunction and a maternal
response featuring systemic inflammation. Hypertension and proteinuria
are considered to be the hallmark’s of preeclampsia[4-6] but the clinical
manifestations of this syndrome are highly heterogeneous. The clinical
findings of preeclampsia can manifest as either a maternal syndrome
(hypertension and proteinuria with or without other multisystem
abnormalities) or as a fetal syndrome (fetal growth restriction, reduced
amniotic fluid, and abnormal oxygenation)[4,5].
DEFINITION OF PREECLAMPSIA:
The classic triad of preeclampsia includes hypertension, proteinuria
and edema. However, there is now universal agreement that edema should
not be considered as part of the diagnosis of preeclampsia.[7–13] Indeed,
edema is neither sufficient nor necessary to confirm the diagnosis of
preeclampsia, because edema is a common finding in normal pregnancy
and approximately one third of eclamptic women never demonstrate
edema.[14]In general, preeclampsia is primarily defined as  hypertension
occurring after 20 weeks of gestation together with  proteinuria.
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Hypertension in pregnancy is defined as
 systolic blood pressure more than or equal to 140mm of Hg
 diastolic blood pressure greater than or equal to 90 mm of Hg
- these measurements must be confirmed by repeated readings over
4 to 6 hours[15,16].
The gold standard for determining proteinuria is the 24-hour urinary
protein excretion. Proteinuria is defined as
 Excretion of more than 300mg of protein/24hr
 Or a urinary protein-to-creatinine ratio of 30mg/mmol
 Or if the above methods are unavailable, as a concentration of
30mg/dL( ≥ 1+ on dipstick) or more in at least 2 random urine
samples collected at least 4 to 6 hours apart.
 Urinary tract infection must be excluded before attributing the
proteinuria to preeclampsia.
Dipstick testing should be used only for screening purposes where
other methods are not available. In all pregnant women who present with
gestational hypertension the presence of proteinuria must be confirmed
with a protein-to- creatinine ratio[15,16] or, preferably, a 24-hour urine
collection.
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The traditional criteria to confirm a diagnosis of preeclampsia (new
onset of hypertension and proteinuria after 20 weeks’ gestation) are
appropriate to use in the majority of healthy nulliparous women. But,
hypertension or proteinuria may be absent in 10 to 15 percent of women
who develop the syndrome of hemolysis, elevated liver enzymes, and low
platelets (HELLP syndrome),[18] and in 20 to 25 percent of those who
develop eclampsia.[19] In recognition that severe disease may occur in the
absence of proteinuria, the Society for Obstetric Medicine Australia and
New Zealand(SOMANZ) has widened these criteria to include the
presence of other systemic manifestations, whether or not proteinuria is
present     ( table-1).[20]
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TABLE -1
SOCIETY FOR OBSTETRIC MEDICINE AUSTRALIA AND NEW
ZEALAND DEFINITION OF PREECLAMPSIA
A clinical diagnosis of preeclampsia can be made when hypertension
arises after 20wk’ gestation and is accompanied by one or more of the
following:
 Renal involvement:
- Proteinuria ≥ 300mg/24 hr or a urine protein/creatinine ratio
≥ 30 mg/mmol
- Serum or plasma creatinine ≥ 0.09mmol/L or oliguria
( <500mL/24hr)
 Hematological involvement:
- Thrombocytopenia
- Disseminated intravascular coagulation
- Hemolysis
 Liver involvement:
- Abnormal liver function( AST and/or ALT >50 IU/L, raised
bilirubin >25 IU/L)
- And/or severe epigastric or right upper quadrant pain.
 Neurologic involvement:
- Convulsions(eclampsia)
- Hyperreflexia with sustained clonus
- Severe headache( persisting, atypical)
- Persistent visual disturbances ( photopsia, scotomata, cortical
blindness, retinal vasospasm)
- Stroke
 Pulmonary edema
 IUGR and/or signs of fetal distress
 Placental abruption
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CLASSIFICATION OF PREECLAMPSIA:
The American College of Obstetricians and gynaecologists classify
preeclampsia dichotomously as non severe and severe.[21]
ABNORMALITY MILD/NON SEVERE SEVERE
Diastolic blood pressure < 110mm of Hg ≥ 110mm of Hg
Systolic blood pressure < 160mm of Hg ≥ 160mm of Hg
Proteinuria ≤ 2+ ≥ 3+
Headache,visual
disturbance
Absent Present
Upperabdominal pain,
oliguria
Absent Present
Serum creatinine Normal Elevated
Thrombocytopenia/
pulmonary edema
Absent Present
Transaminase elevation Minimal Marked
Fetal growth restriction Absent Obvious
PREECLAMPSIA SUPERIMPOSED ON CHRONIC HYPERTENSION:
This is diagnosed  when:
A) There is  a new-onset proteinuria ≥ 300mg/24 hours in hypertensive
women but no proteinuria before 20 weeks of gestation.
B) A sudden increase in proteinuria or blood pressure or platelet count
< 100,000/µL in women with hypertension and proteinuria before 20
weeks gestation[22].
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INCIDENCE AND RISK FACTORS:
The incidence of preeclampsia ranges between 3 and 10 percent in
healthy nulliparous women.[1,12] In these women, preeclampsia is generally
mild, with the onset near term or intrapartum (75 percent of cases), and the
condition conveys only a minimally increased risk for adverse pregnancy
outcome.[7,9,23] In contrast, the severity of preeclampsia are substantially
higher in women with multifetal gestation,[24,25] chronic hypertension,[23,26]
previous preeclampsia,[23,27] pregestational diabetes mellitus,[23] and in those
with preexisting thrombophilias.[28-30]
Generally, preeclampsia is considered a disease of primigravid
women. The risk increases in those who have limited sperm exposure with
the same partner before conception.[31-36] The recent advances in assisted
reproductive technology have introduced several challenges for the
maternal immune system that also increase the risk of preeclampsia.[25,31,37]
The risk factors for preeclampsia are tabulated in table-2.
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ETIOPATHOGENESIS OF PREECLAPMSIA:
The exact etiology of preeclampsia is still unknown. Redmann,
Sargent and coworkers have proposed the two stage hypothesis for
preeclampsia. According to this model, stage 1 is caused by faulty
endovascular trophoblastic remodeling leading to poor placentation which
causes the stage 2 clinical syndrome due to placental oxidative stress and
inflammation. Stage 1 occurs in the first half of pregnancy and stage2 in
the second half of pregnancy.
TABLE-2
RISK FACTORS FOR PREECLAMPSIA
Couple related risk factors:
 Primipaternity and Limited sperm exposure
 Pregnancy after artificial insemination
 Protective effect of partner change in case of previous preeclamptic
pregnancy
Maternal or pregnancy related risk factors:
 Extremes of maternal age.
 Multifetal gestation, preeclampsia in a previous pregnancy
 Chronic hypertension and/or renal disease.
 Maternal chronic inflammatory conditions(e.g., SLE)
 Maternal chronic infections, Maternal low birth weight
 Obesity and insulin resistance and Pregestational diabetes mellitus
 Preexisting thrombophilias, Maternal susceptibility genes
 Family history of preeclampsia, Hydropic degeneration of placenta
 Smoking( reduced risk)
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THE TWO STAGE MODEL OF PRE-ECLAMPSIA
Stage 1
First half of
pregnancy
POOR PLACENTATION NO
SYMPTOMS
Stage 2 Second
half  of pregnancy
PLACENTAL
OXIDATIVE STRESS
AND INFLAMMATION
Overt
preeclampsia
sFlt-1 and  syncytiotrophobalst
factors
Maternal systemic
inflammatory stress
Clinical signs of
preeclampsia
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Such compartmentalization is arbitrary as preeclampsia is a
continuous process. Preeclampsia is more likely a continuum of worsening
disease.
UTERINE VASCULAR CHANGES:
The human placenta receives its blood supply from numerous
uteroplacental arteries that are developed by the action of migratory
interstitial and endovascular trophoblast into the walls of the spiral
arterioles. This transforms the uteroplacental arterial bed into a low-
resistance,low-pressure, high-flow system. The conversion of the spiral
arterioles of the non pregnant uterus into the uteroplacental arteries has
been termed physiologic changes.[38] In a normal pregnancy, these
trophoblast-induced vascular changes extend all the way from the
intervillous space to the origin of the spiral arterioles from the radial
arteries in the inner one third of the myometrium. It is suggested that these
vascular changes are effected in two stages: “the conversion of the
decidual segments of the spiral arterioles by a wave of endovascular
trophoblast migration in the first trimester and the myometrial segments by
a subsequent wave in the second trimester.”[38] These vascular changes
result in the conversion of approximately 100 to 150 spiral arterioles into
distended, tortuous, and funnel-shaped vessels that communicate through
multiple openings into the intervillous space.
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In contrast, pregnancies complicated by preeclampsia or by fetal
growth restriction demonstrate inadequate maternal vascular response to
placentation. In these pregnancies, the above-mentioned vascular changes
are usually found only in the decidual segments of the utero placental
arteries. Hence, the myometrial segments of the spiral arterioles are left
with their musculo elastic architecture, thereby leaving them responsive to
hormonal influences.[38] It is important to note that these vascular changes
may also be demonstrated in a significant proportion of normotensive
pregnancies complicated by fetal growth restriction.[38,39,41] Meekins and
associates[40] have found that endovascular trophoblast invasion is not an
all-or-none phenomenon in normal and preeclamptic pregnancies.
Uterine vascular changes in normal and preeclamptic pregnancy ( FIG-1)
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VASCULAR ENDOTHELIAL ACTIVATION AND PRO AND
ANTIANGIOGENIC PROTEINS  IN  PREECLAMPSIA:
The endothelium is one of the key organs involved in the
pathophysiology of preeclampsia, as evidenced by the prostacyclin,
thromboxane  imbalance[40-42] and impairment of nitric oxide synthesis
which is a potent vasodilator. Endothelial  activation leads to activation of
platelets leading to spiral artery thrombosis thereby reducing the
uteroplacental blood flow. In preeclampsia, endothelial cell dysfunction
and platelet aggregation precede  the increase in thrombin and fibrin
formation.[43-46]
The mechanism by which placental ischemia leads to the clinical
syndrome of preeclampsia is thought to be related to Soluble fms-like
tyrosine kinase 1 (sFlt-1) , a protein that is produced by the placenta. It acts
by binding to the receptor binding domains of vascular endothelial growth
factor (VEGF), and it also binds to placental like growth factor (PLGF).
Increased levels of this protein in the maternal circulation results in
reduced levels of free VEGF and free PLGF, with resultant endothelial cell
dysfunction.[42] Maynard et al.[47] demonstrated that soluble placenta-
derived VEGF receptor (sFlt1), an antagonist of VEGF and PLGF, is
unregulated in preeclampsia, leading to increased systemic levels of sFlt1
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that fall after delivery. Increased sFlt1 in preeclampsia is associated with
decreased circulating levels of free VEGF and PLGF, resulting in
endothelial dysfunction. The magnitude of increase in sFlt levels correlates
with disease severity[48,49,50] . Again, these data are compatible with
decidual angiogenic growth factors, in particular PLGF, as being essential
for early placental development  with a later involvement of sFlt as a fetal
rescue signal steering the maternal response, that is, the degree of maternal
systemic hypertension. This hypothesis is supported by Levine et al.,[49,51]
Recently soluble endoglin (sEng), a placental derived protein is found to
increase months before clinical preeclampsia develops.[52] This soluble
endoglin causes decreased endothelial nitric oxide-dependent
vasodilatation thereby leading to maternal hypertension and endothelial
dysfunction.
IMMUNOLOGY OF PREECLAMPSIA:
Loss of maternal immune tolerance to paternally derived placental and
foetal antigens is another hypothesis cited for preeclampsia syndrome.
Tolerance  dysregulation might also explain an increased risk when the
paternal antigenic load is increased, that is with two sets of paternal
chromosomes- “a double dose” as occurring in molar preganancies and in
trisomy 13.
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HLA-G which is expressed on the cytotrophoblasts act as
immunosuppresants thereby protecting the trophoblast from the cell
mediated destruction of the uterine natural killer cells. In women who are
prone to be preeclamptic the level of HLA-G was found to be low in the
placenta thereby leading to recognition of the fetal cytotrophoblast as
foreign.[53]
Contributors to an enhanced immunologically mediated
inflammatory reaction are from the placental microparticles which are
circulating the maternal body. These placental microparticles  activate the
maternal immune system leading to the maternal immune response
syndrome which leads to oxidative injury of the placenta thereby the stage
2 of the two stage model hypothesis for preeclampsia. This lead to the
formation of a new hypothesis called as the placental debris hypothesis
of preeclampsia.[54]
GENETIC CONFLICT HYPOTHESIS:
According to Haig’s genetic conflict theory,[55] fetal genes are
selected to increase the transfer of nutrients to the fetus, whereas maternal
genes are selected to limit transfer in excess of some optimal level. The
phenomenon of genomic imprinting means that a similar conflict exists
within fetal cells between genes that are maternally derived and genes that
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are paternally derived. The conflict hypothesis suggests that placental
factors (fetal genes) act to increase maternal BP, whereas maternal factors
act to reduce BP. [55,56] . Genome-wide linkage studies have identified at
least three preeclampsia loci showing significant linkage: 2p12 , 2p25 and
9p13.[57]A direct proof of the role of imprinting was recently published by
Oudejans et al.[58] Oudejans et al. confirmed the susceptibility locus on
chromosome 10q22.1.
HOMOCYSTEINE
Homocysteine is a non essential sulfur containing aminoacid .
STRUCTURE OF HOMOCYSTEINE( FIG-2)
HOMOCYSTEINE METABOLISM:
Homocysteine is a non-protein–forming sulfur amino acid whose
metabolism is at the intersection of two metabolic pathways: remethylation
and transsulfuration.
1). In remethylation, homocysteine acquires a methyl group from N-5-
methyltetrahydrofolate or from betaine to form methionine. The reaction
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with N-5-methyltetrahydrofolate occurs in all tissues and is vitamin B12
dependent, whereas the reaction with betaine is confined mainly to the
liver and is vitamin B12 independent. A considerable proportion of
methionine is then activated by ATP to form S-adenosylmethionine
(SAM). SAM serves primarily as a universal methyl donor to a variety of
acceptors. S-adenosylhomocysteine (SAH), the by-product of these
methylation reactions, is subsequently hydrolyzed, thus regenerating
homocysteine, which then becomes available to start a new cycle of
methyl-group transfer. (FIG-1)
2)  In the transsulfuration pathway, homocysteine condenses with serine to
form cystathionine in an irreversible reaction catalyzed by the pyridoxal-
50-phosphate (PLP)–containing enzyme, cystathionine - synthase.
Cystathionine sulfates is excreted in the urine. Thus, in addition to the
synthesis of cysteine, this transsulfuration pathway effectively catabolizes
excess homocysteine, which is not required for methyl transfer.( FIG-3).
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Figure-3 HOMOCYSTEINE METABOLIC PATHWAYS
HYPERHOMOCYSTEINEMIA IN HUMANS:
CAUSES OF HYPERHOMOCYSTEINEMIA[59]
A) ENZYME DEFECTS:
1) Cystathionine synthase ( Homocystinuria-1)
2) Homocysteine methyl transferase( Homocystinuria-2)
3) Methyl THFA reductase deficiency( Homocystinuria-3)
4) Cystathionase  deficiency ( cystathioninuria)
B) ACQUIRED CAUSES
1) Vitamin B12, Folic acid and pyridoxine deficiency.
2) Hypothyroidism, chronic renal failure.
3) Drugs: antifolates, estrogen antagonists.
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HOMOCYSTEINE  IN  NORMAL PREGNANCY:
The normal serum homocysteine level in non pregnant adult  female
range between 5 and 15 µmol/L. Approximately 75 to 85 percent is
protein-bound and 15 to 25 percent is in acid-soluble free forms [60]. Levels
of homocysteine are generally lower in pregnancy because of  decrease in
albumin level, hemodilution or increased demand of methionine both by
mother and fetus. Of this, the decrease in serum  albumin level correlates
well with the serum homocysteine level.
During normal pregnancy the homocysteine levels are significantly
lower in all trimesters compared with non pregnant control values. Walker
et al[61]. in a study of normal pregnant women and non pregnant women,
measured serum homocysteine level by chromatography and found that
the lowest level of homocysteine was  found during the second trimester
and homocysteine raises in the third trimester. However this raise is still
well below the normal non pregnant level.[61,62]
The normal level of homocysteine level during normal pregnancy is:
 First trimester- 3.9-7.3µmol/L
 Second trimester-3.5-5.3 µmol/L
 Third trimester- 3.3-7.5 µmol/L [61,62]
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HOMOCYSTEINE IN PREECLAMPSIA AND OTHER
PREGNANCY RELATED DISORDERS:
Numerous studies have found an association between homocysteine
and various pregnancy related disorders. Klai et al[63] assessed the genetic
makeup of patients with proven  placental vasculopathies and found an
association with MTHFRA1298C polymorphism which leads to
hyperhomocysteinemia. Elevated homocysteine levels are associated with
development of vasculopathy of the placenta. Many hypothesis have been
proposed for the pathogenesis of homocysteine induced vasculopathy and
endothelial dysfunction.
MECHANISMS BY WHICH HOMOCYSTEINE MAY INDUCE
VASCULAR INJURY AND ENDOTHELIAL DYSFUNCTION:
 Homocysteine promotes leukocyte recruitment by upregulating
monocyte chemoattractant protein-1 and interleukin-8 expression
and secretion.[64]
 The thiolactone metabolite of homocysteine can combine with LDL-
cholesterol to produce aggregates that are taken up by vascular
macrophages in the arterial intima; these foam cells may then release
the lipid into atherosclerotic plaques[65].
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 This thiolactone also induces apoptosis in cultured trophoblasts
thereby leading to placental dysfunction[65]
 Homocysteine increases smooth muscle cell proliferation and
enhances collagen production[66] thereby decreasing uteroplacental
flow.
 Prothrombotic effects of homocysteine, include attenuation of
endothelial cell tissue plasminogen activator binding sites, activation
of factor VIIa and V, inhibition of protein C and heparin sulfate,
increased fibrinopeptide A and prothrombin fragments 1 and 2,
increased blood viscosity, and decreased endothelial antithrombotic
activity due to changes in thrombomodulin function[67-72] -
promoting spiral artery thrombosis.
 Oxidative stress by free radicals formed during the oxidation of
reduced homocysteine may directly injure endothelial cells[73,74]
leading to endothelial cell activation.
 Marked platelet accumulation may be secondary to direct
proaggregatory effects of homocysteine or to an impairment in
endothelium-mediated platelet inhibition[75,76].
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 Prolonged exposure of endothelial cells to homocysteine reduces the
activity of dimethylarginine dimethylaminohydrolase, the enzyme
that degrades asymmetric dimethylarginine, an endogenous inhibitor
of nitric oxide synthase; this impairs the production of nitric
oxide[75,77]. This may contribute to impaired endothelium-dependent
vasodilation of both conduit and resistance vessels[78,79,80] in the
placenta.
 Homocysteine also decreases the  invasion in cultured trophoblast
by decreasing matrix metalloproteinase-2,-9 expression which are
essential for invasion.[81]
HYPERHOMOCYSTEINEMIA IN PREECLAMPSIA
REVIEW OF CLINICAL STUDIES:
Numerous studies have proved the association of
hyperhomocysteinemia in preeclampsia.[82-89]. Similarly the level of
homocysteine correlated with the severity of preeclampsia[86].
Md.Mazammel hoque et al[82] compared the homocysteine levels in
healthy pregnant, preeclamptic and eclamptic pregnant women and found
that homocysteine levels are significantly raised in both preeclampsia  and
eclampsia, but in eclampsia the severity of elevation is more compared to
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that in preeclampsia.   Mahal M et al[83] compared serum homocysteine and
HDL levels in preeclamptic/ eclamptic mother and found that both HDL
and homocysteine are increased in women with preeclampsia/eclampsia.
Singh urmila et al[84] studied 90 women and found that
homocysteine levels were significantly different between non preeclamptic
and preeclamptic mothers . In that study, homocysteine levels correlated
directly with the degree of hypertension. And he proved that maternal
homocysteine levels in normal pregnant women were significanty lower
than non pregnant levels. Similarly, Hasanzadeg et al [85] and Stolkova et
al[86] showed that serum homocysteine levels were significantly raised in
mothers with preeclampsia.
Ingec et al[89] compared the homocysteine levels among mild and
severe  preeclampsia  with eclampisa and concluded that homocysteine
levels are significantly elevated in severe preeclampsia and eclampsia,
with  significant difference between the mild and severe preeclamptic
group. However in that study there was no difference between normal
pregnant women and women with mild preeclampsia.  Stolkova et al[86] did
a study on the distribution of homocysteine levels in preeclamptic women
and found that there is an association between serum homocysteine levels
and the severity of preeclampsia.
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Makedos and papanicollou et al[87] compared maternal
homocysteine, folic acid and B12 levels among women with preeclampsia
and found that hyperhomocysteinemia is associated with poor maternal and
fetal outcome and found that hyperhomocysteinemia occurred in
preeclampsia independent of maternal folate and B12 levels.
The Hordaland  study[97] showed that women with Homocysteine
levels more than 15µ/L are more likely to suffer from pregnancy related
complications and are also associated with poor maternal and fetal
outcome.
Baksu et al [88] studied the homocysteine levels in pregnancies
complicated with severe and non severe preeclampsia and found that at a
homocysteine level of above 15µmol/L the maternal and fetal morbidities
increased and also proved that homocysteine levels differed significantly
among the severe and non severe group.
HYPERHOMOCYSTEINEMIA IN OTHER PREGNANCY
RELATED CONDITIONS:
 Hyperhomocysteinemia is found to have some association in neural
tube defects.[90]
 Hyperhomocysteinemia in amniotic fluid is associated with small for
gestational babies.[91]
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 Hyperhomocysteinemia is an independent marker for low birth
weight.[92]
 Hyperhomocysteinemia together with uterine artery Doppler could
predict IUGR[93] and hyperhomocysteinemia in preeclampsia is
associated with IUGR.[87] The Hordaland homocysteine study[97]
showed that there is an association between hyperhomocysteinemia
and IUGR independent  of preeclampsia.
 Hyperhomocysteinemia in preeclampsia is inversely related to
insulin sensitivity.[94]
 Hyperhomocysteinemia is a independent risk factor for the
development of placental abruption and infarction.[95,97]
 Hyperhomocysteinemia is one of the causes for recurrent pregnancy
losses in the first trimester.
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MATERIALS AND METHODS
SETTING
This study was conducted in the Department of Obstetrics And
Gynaecology at RSRM-Lying in Hospital, Stanley Medical College and
Hospital in collaboration with the department of Biochemistry and Clinical
pathology.
ETHICAL APPROVAL
Obtained
STUDY DURATION
This study was conducted over a period of 1 year from September
2010 to September 2011.
STUDY POPULATION
Pregnant women attending the RSRM hospital were screened and
those who were eligible according to the inclusion criteria and exclusion
criteria, were included in the study after obtaining proper detailed consent
from the patients.
TYPE OF STUDY
It was a cross sectional case control study.
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INCLUSION CRITERIA
 Pregnant women in 28-40weeks who were under regular
check up and who are under regular iron and folic acid
prophylactic therapy were included in the study.
EXCLUSION CRITERIA
 Chronic hypertension
 Chronic kidney disease/ liver disease
 Diabetes mellitus or Gestational diabetes
 Under anti folate drugs ( anti-epileptics)
 Multiple pregnancies and hypothyroid women.
 h/o thromboembolism like deep vein thrombosis etc..
 h/o recurrent miscarriage
 h/o neural tube defects
 presence of megaloblastic or dimorphic anemia in the peripheral
smear study.
 Patients who are not under any iron supplements.
 Patients who are not willing to get included in the study.
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METHODS
120 patients who came to RSRM are included in the study after
obtaining their consent and fulfillment of the inclusion and exclusion
criteria. All the patients underwent a detailed history taking and
examination as mentioned in the proforma. Then these patients were
categorized into three groups as normal pregnancy( group 1) n=40, women
with mild preeclampsia( group2)n=40 and women with severe
preeclampsia(group3) n=40 according to the American College of
Obstetric and Gynaecology guidelines.
GROUP CRITERIA AS
GROUP 1
Normal pregnant
women with
singleton pregnancy
(28-40 weeks)
BP<140/90
GROUP 2
Women
with mild
preeclampsia(28-40
weeks)
BP >140/90
BP<160/110  with  1+
proteinuria
GROUP 3
Women
with severe
preeclampsia
(28-40 weeks)
BP ≥ 160/110 with
2+/3+ proteinuria  or
imminent signs.
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Study subjects of each group were apparently matched with respect
to gestational age. All these patients were subjected to routine blood
investigations like complete hemogram,urine routine, renal function test,
liver function test, serum fibrinogen, uric acid, CTG, ultrasonogram and
fundus examination. Urinary 24 hrs protein excretion was done for all
patients included in the study. Urine cultue were done for the appropriate
patients. Peripheral smear study was done for all patients to exclude
megaloblastic anemia and dimorphic anemia. Serum folate and vitaminB12
level could not be estimated because of limited resources. Hence the
presence of megaloblastic or dimorphic anemia are taken as indirect
indictors of folate or B12 deficiency and these patients were ruled out of
the study. Once vitamin deficiencies are excluded serum homocysteine
level was estimated.
For the measurement of serum homocysteine, 5 mL of blood was
drawn from the antecubital vein after overnight fasting and the specimen
was transported immediately to lab and centrifugation was done at
3000rpm for 5-7 mts and the clear serum is transferred to a plastic vial and
stored in refrigerator until analysis. Serum homocysteine was measured by
fluorescence polarization immunoassay (FPIA) run on Abbott’s AxSYM
machine using Abbott’s kit.
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All these patients were followed up till delivery. Maternal morbities
like acute kidney injury, pulmonary edema, HELLP syndrome, DIC,
abruption, atonic PPH, etc. are watched for and recorded appropriately.
Similarly the birth weight, the presence of IUGR, IUD, neonatal mortality
were also noted. Also the one minute APGAR score, the duration of NICU
stay were noted. The NICU stay was divided into three groups as babies
with no NICU stay, stay less than 3 days and stay for more than 3 days.
Similarly the maturity of the foetus was also noted. If preterm whether it
was spontaneous or iatrogenic was noted. All these values are entered in
the master chart for comparison and analysis. A standard proforma was
used to record all the variable for every individual patient as given in the
annexure-A.
STATISTICAL ANALYSIS:
Statistical analysis was performed with SPSS software (version
15.00 for windows). To find out the statistical significance, one way
ANOVA ( analysis of variance) test and student ‘t’ test were done. For the
purpose of this study 95% confidence interval has been chosen and ‘p’
value <0.05 has been taken as significant.
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OBSERVATION AND RESULTS
MATERNAL GESTATIONAL AGE DISTRIBUTION
AMONG THE GROUPS
Gestational  age Group 1 Group 2 Group 3
28-32 wks 1 1 2
33-36 wks 15 14 26
37-40 wks 24 25 12
MEAN
GESTATIONAL
AGE
36.58 36.45 35.9
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MATERNAL GESTATIONAL AGE AMONG THE 3 GROUPS
40
COMPARISON OF MATERNAL GESTATIONAL AGE BETWEEN
GROUP 1,2 AND 3 – ANOVA TEST
GESTATIONAL
AGE GROUPS N MEAN S.D
Normal
Pregnancy
(GROUP 1)
40 36.58 1.947
Mild
Preeclampsia
(GROUP 2)
40 36.45 1.663
Severe
Preeclampsia
(GROUP 3)
40 35.90 1.336
Total 120 36.31 1.679
Sum of
Squares df
Mean
Square F Sig. p value
GA
Between
Groups 10.317 2 5.158 1.855 .161
˃ 0.05Within
Groups 325.275 117 2.780
Total 335.592 119
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POSTHOC TEST MULTIPLE COMPARISONS
In our study there was no statistically significant difference among the
three groups with respect to the maternal gestational age.
Dependent
Variable (I) Group (J) Group
Mean
Differen
ce (I-J)
Std.
Error Sig.
p
VALUE
GESTATIO
NAL AGE
Normal
Pregnancy
Mild
Preeclampsi
a
.13 .373 .940 ˃ 0.05
Severe
Preeclampsi
a
.68 .373 .171 ˃ 0.05
Mild
Preeclampsia
Normal
Pregnancy -.13 .373 .940 ˃ 0.05
Severe
Preeclampsi
a
.55 .373 .307 ˃ 0.05
Severe
Preeclampsia
Normal
Pregnancy -.68 .373 .171 ˃ 0.05
Mild
Preeclampsi
a
-.55 .373 .307 ˃ 0.05
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HOMOCYSTEINE LEVEL AMONG GROUP 1-NORMAL
PREGNANT WOMEN
43
HOMOCYSTEINE LEVEL AMONG GROUP 2-MILD
PREECLAMPSIA
44
HOMOCYSTEINE LEVEL AMONG GROUP 3-SEVERE
PREECLAMPSIA
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CORRELATION OF MATERNAL HOMOCYTEINE AMONG THE
THREE GROUPS
N Mean
Std.
Deviation
Homocysteine Normal
Pregnancy 40 6.650 1.5785
Mild
Preeclampsia 40 11.583 2.3770
Severe
Preeclampsia 40 16.670 3.3467
Total 120 11.634 4.8181
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CORRELATION OF MATERNAL HOMOCYTEINE AMONG THE
THREE GROUPS
Sum of
Squares df
Mean
Square F Sig.
p
value
Homocystein
e
Betwee
n
Groups
2008.16
8 2
1004.08
4
155.73
6
.00
0 <
0.00
1Within
Groups 754.342
11
7 6.447
Total 2762.51
0
11
9
Post Hoc Tests Multiple Comparisons
Depende
nt
Variable (I) Group (J) Group
Mean
Differen
ce (I-J)
Std.
Error Sig.
p value
Homocys
teine
Normal
Pregnanc
y
Mild
Preeclampsia -4.932 .5678 .000
<0.001
Severe
Preeclampsia -10.020 .5678 .000
<0.001
Mild
Preeclam
psia
Normal
Pregnancy 4.932 .5678 .000
<0.001
Severe
Preeclampsia -5.087 .5678 .000
<0.001
Severe
Preeclam
psia
Normal
Pregnancy 10.020 .5678 .000
<0.001
Mild
Preeclampsia 5.087 .5678 .000
<0.001
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In our study there was a significant difference between the homocysteine
levels among all the three groups.
CORRELATION OF MATERNAL HOMOCYSTEINE LEVEL
WITH FETAL MATURITY
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PRETERM DISTRIBUTION AMONG THE 3 GROUPS
CORRELATION OF MATERNAL HOMOCYSTEINE LEVEL
WITH FETAL MATURITY
n
Average
homocysteine
level
STD
Deviation t df
Sig.
(2-
tailed)
p
value
In
preterm
group
21
15.95 4.08
4.948 118 .000 <
0.001
In term
group
99 10.72 4.47 5.249 31.045 .000 <0.001
In our study, there is an association between maternal homocysteine
level and fetal maturity.Most of the prematurity in the severe preeclamptic
group (76%) was iatrogenic.
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CORRELATION BETWEEN MATERNAL HOMOCYSTEINE
LEVEL AND BIRTH WEIGHT
homocysteine
level
0-
4.9µmol/L
5-9.9
µmol/L
10-14.9
µmol/L
15-19.9
µmol/L
20-24.9
µmol/L
<2.5 Kg 0 2 11 11 3
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CORRELATION BETWEEN MATERNAL HOMOCYSTEINE
LEVEL AND BIRTH WEIGHT
n
Average
homocysteine
level
STD
Deviation t df
Sig.
(2-
tailed)
p
value
<2.5
Kg
27 15.4 4.19 5.070 118 .000
<
0.001>2.5
Kg
93 10.54 4.44 5.228 44.291 .000
In our study, there is an association between maternal homocysteine
level and the neonatal birth weight.
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CORRELATION BETWEEN MATERNAL HOMOCYSTEINE
LEVEL AND  1 MINUTE APGAR SCORE
APGAR SCORE
Average
homocysteine level
µmol/L
n
Upto 3 12.7 4
4-6 13.12 13
7-10 11.27 101 ( IUD=2)
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CORRELATION BETWEEN MATERNAL HOMOCYSTEINE
LEVEL AND 1 MINUTE  APGAR SCORE
ANOVA
Sum of
Squares df
Mean
Square F Sig.
p value
Between
Groups 45.157 2 22.578 .995 .373
>0.05WithinGroups 2608.822 115 22.685
Total 2653.979 117
POST HOC TESTS MULTIPLE COMPARISONS
(I) Apgar (J) Apgar
Mean
Difference (I-
J) Std. Error Sig. p value
≤ 3 4-6 -.415 2.7233 .987 ˃ 0.05
≥ 7 1.434 2.4282 .826 ˃ 0.05
4-6 ≤ 3 .415 2.7233 .987 ˃ 0.05
≥ 7 1.849 1.4034 .388 ˃ 0.05
≥ 7 ≤ 3 -1.434 2.4282 .826 ˃ 0.05
4-6 -1.849 1.4034 .388 ˃ 0.05
In our study, there was no association between maternal homocysteine
level and 1 minute APGAR score.
53
CORRELATION BETWEEN MATERNAL HOMOCYSTEINE
LEVEL AND  DURATION OF  NICU STAY
NO NICU
STAY
NICU STAY <3
DAYS
NICU STAY >3
DAYS
No of babies
n 96 10 12
MEAN
Homocysteine
level µmol/L
11.05 12.09 15.98
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CORRELATION BETWEEN MATERNAL HOMOCYSTEINE
LEVEL AND  DURATION OF  NICU STAY
n
Average
homocysteine
level
STD
Deviation t df
Sig.
(2-
tailed)
p
value
No
nicu
96 10.9 4.65 -.772 104 .442
˃ 0.05
<3
days
nicu
10 12.09 4.43
-.804 11.171 .438
n
Average
homocysteine
level
STD
Deviation t df
Sig.
(2-
tailed)
p
value
No
nicu
96 10.9 4.65 -
3.645 106 .000 <
0.001>3
days
nicu
12 15.98 3.59 -
4.450 15.996 .000
n
Average
homocysteine
level
STD
Deviation t df
Sig.
(2-
tailed)
p
value
NICU<
3
DAYS
10 12.09 4.43 -
2.276 20 .034 <
0.05
Nicu>
3 days
12 15.98 3.59 -
2.232 17.327 .039
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In our study, there was no association between homocysteine level and
NICU stay for less than 3 days. However there is an association between
maternal homocysteine level and babies requiring NICU stay for more than
3 days.
CORRELATION BETWEEN MATERNAL
HOMOCYSTEINE AND IUGR
n
Average
homocysteine
level
STD
Deviation t df
Sig.
(2-
tailed)
p
value
IUGR 2 21.55 3.46 3.035 118 .003
<
0.01
OTHERS 118 11.47 4.67 4.054 1.062 .143
In our study , there is an association between maternal homocysteine
level and fetal IUGR.
CORRELATION OF HOMOCYSTEINE WITH MATERNAL
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MORBIDITY
Homocysteine
level
0-
4.9µmol/L
5-9.9
µmol/L
10-14.9
µmol/L
15-19.9
µmol/L
20-24.9
µmol/L
MORBIDITY 0 0 0 6 1
In our study all the maternal morbidities occurred in mothers with
homocysteine level of more than 15µ/L.
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CORRELATION OF HOMOCYSTEINE WITH
MATERNAL MORBIDITIY
n
Average
homocystein
e level
STD
Deviatio
n
t df
Sig.
(2-
tailed
)
p
value
Maternal
morbidit
y
7 18.38 1.83 4.06
2 118 .000 <
0.00
1Normal 11
3
11.21 4.63 8.77
4
11.61
9 .000
In our study, there is an association between maternal homocysteine
level and various maternal morbidities in preeclamptic mothers.
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CORRELATION OF MATERNAL HOMOCYSTEINE LEVEL
WITH PERINATAL MORTALITY
n
Average
homocysteine
level
STD
Deviation t df
Sig.
(2-
tailed)
p
value
Perinatal
mortality
4 18.85 2.27 3.159 118 .002
<
0.01Normal 116 11.38 4.69 6.128 3.942 .004
In our study, there is an association between maternal homocysteine
level and fetal perinatal mortality.
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CORRELATIION OF HOMOCYSTEINE LEVEL WITH VERY
POOR MATERNAL AND FETAL OUTCOMES IN THE SEVERE
PREECLAMPSIA GROUP
GROUP
3
n MEAN S.D variance p VALUE
Very poor
outcome
8 19.6 2.61 6.81
< 0.001Others 32 16.06 3.26 10.6
In our study homocysteine levels (in the severe preeclamptic group)
differed significantly among mothers with poor maternal and fetal outcome
from others.
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DISCUSSION
In our study 120 patients were included after fulfilling the inclusion
and exclusion criteria with 40 patients in each group- normal pregnany,
mild preeclampsia and severe  preeclampsia.
GESTATIONAL AGE AMONG THE THREE GROUPS:
The average gestational age for the 3 groups were 36.58 wks for
group 1, 36.45 wks for group2 and 35.9 wks for group 3. There was no
statistically significant difference in the gestational age of the three groups
(p > 0.05). In our study 51% of women were in 36-40 weeks of gestation,
45% were between 33-36 weeks of gestation and 4% were between 28-32
weeks of gestation.
HOMOCYSTEINE  DISTRIBUTION AMONG THE 3 GROUPS:
TABLE-1
GROUP
MEAN
homocysteine
level
(µmol/L)
RANGE mean± 2SD
GROUP 1
(Normal
pregnancy)
6.65 4.3-10.7 5.07-8.23
GROUP 2
(Mild
preeclampsia)
11.58 4.7-15.5 9.2-13.96
GROUP 3
(severe
preeclampsia)
16.67 9.5-24.0 13.32-20.02
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Table-1 shows the homocysteine level in the different groups. In our
study the mean homocysteine level among normal pregnant mothers was
6.65 µmol/L. this is almost same as the homocysteine level as 6.86 µmol/L
in the study conducted by mozammel hoque et al[82]. In another study done
at Canada the mean homocysteine level at 36-42wks among normal
pregnant women was 5.5 µmol/L [61]. In the study conducted by Stolkova
et al[86] the mean homocysteine level was 6.24 µmol/L almost similar to
our study.  In our study the mean homocysteine level in patients with mild
preeclampsia was 11.58 ±2.38 µmol/L. In the study done by hasanzadeh et
al[85] the homocysteine level among mild preeclampsia was 10.4±2.3
which is close to our study.
In our study the homocysteine level among the severe preeclampsia
group was 16.67±3.35 µmol/L. This is close to the study of hasanzadeh et
al [85] where the homocysteine level was 13.8±7. In  another study by ingec
et al[89] the homocysteine level among severe preeclamptic women was
16.7±10.1 µmol/L which is almost similar to our study.
CORRELATION OF HOMOCYSTEINE LEVEL WITH
PREECLAMPSIA:
On comparing group 1 and 2, in our study there was a statistically
significant difference between the homocysteine level among normal
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pregnant women and women with mild preeclampsia ( p <0.001) .
Similarly between group 1 and group 3 the serum homocysteine level
differed significantly ( p<0.001) . So, our study proves that serum
homocysteine is raised in preeclampsia and there is an association between
preeclampsia and hyperhomocysteinemia. Several studies have proven this
concept that preeclampsia is associated with hyperhomocysteinemia[82-90].
The large Hordaland homocysteine - a population based study[97] done over
a period of 7 years in a population of about 7,053, concluded that
hyperhomocysteinemia is a risk factor for preeclampsia.
CORRELATION OF HYPERHOMOCYSTEINEMIA WITH
SEVERITY OF PREECLAMPSIA:
Also in our study there was a significant difference in homocysteine
level between  mothers with mild and severe preeclampsia (p<0.001).
Similar findings were also noted in the study conducted by Stolkova et
al[86] .where maternal homocysteine level correlated with the severity of
preeclampsia. Our study shows that maternal homocysteine level  is
directly associated with the severity of preeclampsia. In the study by Ingec
et al[89] there was a significant difference between mild and severe
preeclampsia, however homocysteine levels did not vary significantly
between normal pregnant women and women with mild preeclampsia.
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Baksu et al [88] in his study showed that levels differed significantly among
the severe and non severe group. However another study by Hasanzadeh
et al[85] failed to show an association between the severity of preeclampsia
and maternal homocysteine level although this study confirmed
hyperhomocysteinemia in preeclampsia[85]. These findings points  that
hyperhomocysteinemia due to its direct vascular endothelial injury and
prothrombotic effect on the coagulatory system has  a potential role in the
pathogenesis of preeclampsia.
CORRELATION OF HOMOCYSTEINE LEVEL WITH FETAL
MATURITY:
In our study, 21 out of 120 fetus were preterm. Out of this 21, 17
preterm births (81%) occurred in the severe preeclampsia group , 3 (18%)
in the mild preeclamptic group and 1(1%) in the normal pregnancy group.
There were no iatrogenic preterm birth in the normal pregnancy and mild
preeclamptic group. However 14 out of the 17 preterm births in the severe
preeclampsia group (82%) are due to iatrogenic preterm birth primarily
done to terminate pregnancy. In our study the incidence of prematurity
among the preeclamptic group was 25%. This is almost same as reported
by Das et al (1998) as 27%. According to Mudaliar, Menon, toxemias
account for 22% of preterm delivery .The maternal homocysteine level was
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significantly elevated in the preterm group ( p < 0.001) when compared to
the term group.The Hordaland homocysteine study done at western
Norway showed  that hyperhomocysteinemia in a population  is a risk
factor for preterm/prematurity[97] of the fetus.
CORRELATION OF HOMOCYSTEINE LEVEL WITH BIRTH
WEIGHT:
In our study 27 new borns were of low birth weight. The average
homocysteine level of the  mothers of these low birth weight babies was
15.4 µmol/L. This was statistically different from the mean homocysteine
level of the rest of the mothers -10.4 µmol/L( p<0.001). Our study shows
that there is a direct association between maternal hyperhomocysteinemia
and  fetal birth weight. In the study by Baksu et al[88], maternal
homocysteine level cut-off value of 15µ/L correlated well with mothers
with low birth weight babies. In a study done by grandone et al[91] , it was
shown that hyperhomocysteinemia in amniotic fluid was associated with
small for gestational age babies and low birth weight independent of
preeclampsia. The Hordaland Homocysteine study[97] showed that
hyperhomocysteinemia is a risk factor for low birth weight.
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CORELATION OF MATERNAL HOMOCYSTEINE LEVEL WITH
1 MINUTE APGAR SCORE:
In our study, we divided the neonates into 3 groups based on their 1
minute APGAR score as group1( APGAR≤ 3), group 2(APGAR 4-6) and
group 3 ( APGAR ≥ 7). Though to the best of our knowledge we could not
find any studies comparing maternal homocysteine level with APGAR
score , we tried to find out whether there was any association  between the
two. However, on comparing we could not find any statistically significant
difference between the three groups (p>0.05). In our study  there is no
association between maternal homocysteine levels and  APGAR score
done at 1 minute.
CORRELATION BETWEEN MATERNAL HOMOCYSTEINE AND
DURATION OF NICU STAY
We divided the neonates  into 3 groups based on the need for NICU
stay. Group 1 ( no NICU stay), group 2( NICU stay ≤ 3 days) and group 3
( NICU stay > 3 days) and tried to correlate the hyperhomocysteinemia
with these three groups. On analysis, we found that there is no association
between homocysteine levels and the need for NICU for ≤ 3 days.
However the level of homocysteine was significantly higher in mothers of
neonates who required more than 3 days of NICU care. We could not find
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any study correlating homocysteine with duration of NICU stay. From  our
study, maternal hyperhomocysteine can predict a group of mothers who
might require prolonged neonatal care for their babies.
CORRELATION BETWEEN MATERNAL HOMOCYSTEINE
LEVEL AND FETAL IUGR:
In our study, there was an association between maternal
hyperhomocysteinemia and fetal IUGR (p<0.01). This is not surprising
because of the known effects of homocysteine on placenta in the placental
vasculopathy[63]. Also homocysteine decreases the invasion of
trophoblasts[81]. However preeclampsia by itself can produce IUGR. The
Hordaland Homocysteine study[97] showed that maternal
hyperhomocysteinemia due to MTHFR 677C.T polymorphism is
associated with fetal growth restriction.
CORRELATION BETWEEN MATERNAL HOMOCYSTEINE
LEVEL AND MATERNAL MORBIDITIES:
Studies have shown an association between maternal
hyperhomocysteinemia and abruption[95,97]. In our study 7 mothers in the
severe preeclampsia group suffered from maternal morbidities like
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abruption, acute kidney injury, pulmonary edema, HELLP syndrome and
atonic post partum hemorrhage. On comparing the homocysteine level we
found that there is significant association between maternal homocysteine
level and later morbidities(p<0.001). All the 7 mothers had a homocysteine
level of more than 15µmol/L and all these morbidities occurred only in
severe preeclampsia. This is similar to the study of Baksu et al[88] where a
cut-off value of 15µmol/L for maternal homocysteine level predicted all
maternal morbidities. Larger studies are needed to confirm the level of
maternal homocysteine level  which can exactly predict the maternal
morbidities and mortality. Hyperhomocysteinemia has been accepted as a
cause of placental abruption .[97,98] In our study there was no maternal
mortality.
CORRELATION BETWEEN MATERNAL HOMOCYSTEINE
LEVEL AND PERINATAL MORTALITY:
In our study the number of perinatal deaths was four. 2 were due to
intra uterine deaths and 2 were due to neonatal mortality. There was a
significant difference between homocysteine level of mothers with
perinatal death and without perinatal death (p<0.01). The Hordaland
Homocysteine study  showed that  there is an association between
hyperhomocysteinemia and still births and adverse pregnancy outcomes.[97]
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Similar to the study of Baksu et al[88] , a cut-off value of maternal
homocysteine level of 15µmol/L in our study, had a correlation with the
perinatal mortality.
CORRELATIION OF HOMOCYSTEINE LEVEL WITH VERY
POOR MATERNAL AND FETAL OUTCOMES IN THE SEVERE
PREECLAMPSIA GROUP:
In our  study, we tried to compare the homocysteine levels among the
severe preeclampsia group . We divided the severe preeclampsia group
into mothers with very poor maternal and fetal outcomes like
complications of preeclampsia, IUD,IUGR and neonatal mortality and
mothers without these features. We compared the homocysteine level
among these two groups and found that homocysteine level was
significantly elevated in mothers with  poor maternal and fetal outcomes in
the severe preeclampsia group. This suggests that hyperhomocysteinemia
per se is associated with poor outcomes independent of preeclampsia.
However large studies are needed in pregnancies before attributing
hyperhomocystinemia to such an outcome.
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SUMMARY OF THE STUDY
120 pregnant women were selected for our study. There were three
groups in our study as women with normal pregnancy, women with mild
preeclampsia and women with severe preeclampsia. These women were
included after they fulfilled the inclusion and exclusion criteria. Serum
homocysteine level was estimated in all the women and all of them were
followed upto pregnancy and maternal and fetal outcomes were recorded.
The mean age of women in group 1 was 36.58 weeks , 36.45 weeks
for group 2 and 35.9 weeks for group 3. There was no statistically
significant difference in the age of the three groups.The homocysteine
level among the normal pregnant women was 6.65±3.16 µmol/L,
11.58±4.76 µmol/L for the mild preeclmaptic group and 16.67±6.7 µmol/L
for  women with severe preeclampsia.  Women with severe preeclampsia
had the highest homocysteine level followed by mild preeclampsia and
then normal pregnant women. All these values were statistically significant
implying that homocysteine level differed significantly between women
with and without preeclampsia and also correlated with the severity of
preeclampsia.
With respect to the maternal and fetal outcome,  elevated homocysteine
levels correlated with all  maternal morbidities. All these morbidities
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occurred in mothers with homocysteine levels of more than 15 µmol/L .
The average homocysteine levels in the morbidity group was 18.38±3.66
µmol/L and the group with no morbidity had a homocysteine level of
11.21± 9.26 µmol/L Elevated maternal homocysteine levels were
associated with increased fetal IUGR, fetal preterm birth, low birth weight,
prolonged NICU stay of the neo-nate and increased perinatal  mortality.
All the mothers who had IUD, neonatal mortality and IUGR had a
homocysteine level of more than 15 µmol/L. However maternal
homocysteine level  did not correlate with the 1 minute APGAR score of
the newborn and also with newborns who needed NICU stay of less than 3
days. Even among the severe preeclamptic women, hyperhomocysteinemia
per se can cause poor maternal and fetal outcomes independent of
preeclampsia.
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CONCLUSIONS FROM THE STUDY
 Preeclampsia is associated with Hyper homocysteinemia.
 In preeclampsia, homocysteine levels are directly related to the
severity of preeclampsia.
 A maternal homocysteine level of more than 15µmol/L can be used
to expect poor maternal and fetal outcome until further larger studies
predict the exact value.
 Maternal hyperhomocysteinemia is associated with prematurity, low
birth weight and increased perinatal mortality.
 Maternal hyperhomocysteinemia can predict a group of mothers
whose babies might require  special  prolonged neonatal care
 Hyperhomocysteinemia increases maternal morbidities especially
placental abruption.
 There is no association between maternal homocysteine level and
neonatal APGAR score done at 1 minute.
 Similarly maternal hyperhomocysteinemia cannot predict babies
who need ≤ 3 days of NICU care from babies whom may not need
NICU care.
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 Since nutritional deficiencies like B12, folate and B6 are known to
produce hyperhomocysteinemia, better nutritional  care to the at risk
mothers should be done till further studies confirm the role of
hyperhomocysteinemia in preeclampsia.
 Though hyperhomocysteinemia is known to occur in preeclampsia,
the cause for the elevation in preeclampsia is still not known.
Further studies are needed to know the cause for
hyperhomocysteinemia in preeclampsia which may help in the
pharmacological management of pregnant mothers.
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PROFORMA
Name:                 age:                            Inpatient no:                                D.O.A:
LMP:                  EDD:                       obstetric code: D.O.D:
GESTATIONAL AGE:
COMPLAINTS OF:
Headache Yes/no
Visual disturbance Yes/no
Upper abdominal pain Yes/no
Oliguria Yes/no
Jaundice Yes/no
Symptoms suggestive of  DVT Yes/no
Convulsions Yes/no
HISTORY OF:
chronic hypertension yes/no
diabetes mellitus yes/no
chronic renal disease/hypothyroidsm yes/no
cardio vascular disease yes/no`
Thrombo embolism Yes/no
Deep vein thrombosis or DVT prophylaxis Yes/no
Repeated miscarriage Yes/no
Neural tube defects Yes/no
Folic acid supplementation Yes/no
Previous h/o PIH Yes/no
ON EXAMINATION:
Conscious:                            orientation:                                 dyspnea:
Pallor: icterus:                          pedal edema:
Signs of  DVT:
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Anthropometry:
Height:                                                        weight:
Vitals:
Pulse rate:        respiratory rate:          Bood pressure: temperature:
Cvs:                 RS:                           CNS:
Abdomen:
Uterus size:
uterus acting: yes/no                                         Tense/tenderness:
Fetal position: FH:
Others:
p/v:
INVESTIGATIONS:
COMPLETE HEMOGRAM:
Hb:            Tc:                    Dc:                         platelet:
ESR: Hematocrit:
FBS:                                                                 PPBS:
Blood urea:                                     serum creatinine:                      electrolytes:
Serum uric acid:                             serum fibrinogen:
LFT:
Total bilirubin: ALT:                                        AST:
SAP:                              Total protein:                                  albumin:
Urine:
Albumin: sugar:                                        deposits:
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24 hours urinary protein:
Urine culture with colony count:
Peripheral smear study:
Fundus examination:
Serum homocysteine :
USG:
CTG:
DIAGNOSIS:
MATERNAL MORBIDITIES:yes/no   if yes:
MATERNAL MORTALITY: yes/no
PERINATAL OUTCOME: dead/ alive
Birth weight:         APGAR score:           IUGR: yes/no          NICU : yes/no
Neonatal mortality: yes/no   term/preterm     preterm: spontaneous/iatrogenic
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MASTER CHART
homogr1 homogr2 homogr3 GA Gr1 GA Gr2 GA Gr3
T/PT
Gr1
T/PT
Gr2 T/PT Gr2 T/PT Gr3
7.3 10.5 16.3 31 37 35 T T T
7.6 13.1 19.1 34 39 38
T
Pt(
spont) PT (iatro)
8.2 11.4 14.8 37 38 36 T T T
7.2 13.2 18.6 35 33 36 T T PT(iatro)
7.8 12.1 21.1 37 37 32 T T T
6.6 15.2 15.7 38 35 35 T T PT(iatro)
7 13.3 17.3 39 38 37 T T T
6.8 4.7 12 36 34 36 T T PT(iatro)
10.4 9 14 37 37 37 T T T
6.3 11 15.4 33 38 36 T T T
5.9 9.5 12 38 36 38 T T PT(iatro)
6.5 10.4 16.5 34 37 32 T T PT(iatro)
7.1 10 17.5 39 38 35 T T PT(iatro)
6.8 15.3 15 37 34 37 T T T
10 12.5 16.6 35 39 36 T T PT(iatro)
8.2 15.5 15.5 38 38 36 T T T
7.5 9 19 34 35 37 T T T
7 9 13.6 39 37 36
T T
PT(
spont)
9 8.5 18.8 35 38 36 T T T
6.8 8.5 24 37 33 34 T T PT(iatro)
4.7 12.3 22.4 37 37 36 T T T
6.6 15.4 17.4 39 38 36 T PT(spont) T
5.5 13.5 13.8 35 38 38 T T T
4.6 12.5 19.9 38 35 37 T T PT(iatro)
4.3 13 22.6 39 37 35 T T PT(iatro)
6.4 9.5 14 35 37 35 PT(
spont) T PT(iatro)
5.6 13 19.5 38 35 35 T T T
6.9 11.4 19.8 36 38 37 T T T
7.1 9.5 22.5 35 37 36 T T T
5.2 11.4 16.7 37 36 36 T T T
6.3 12.2 19 34 35 35 T T PT(iatro)
4.9 11.7 14.7 38 32 38 T T T
4.6 15.3 14.2 37 36 35 T T T
5.8 12.7 9.5 35 37 36 T T T
7.1 11.9 17 39 37 36 T T PT(iatro)
6 12 16.8 39 35 37 T T PT(spont)
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10.7 15.3 13.6 36 37 35 T PT(spont) T
4.8 9.6 15.8 37 37 37 T T T
4.3 9.8 14.9 38 36 35 T T T
4.6 9.6 9.9 38 37 36 T T PT(spont)
LBW Gr
1
LBW
Gr2
LBW
Gr3
IUGR
Gr1
IUGR
Gr2
IUGR
Gr3
NICU
Gr1
NICU
Gr2
NICU
Gr3
N N N NO NO N NA NA N
N N YES NO NO YES NA <3 DAYS <3DAYS
N YES N NO NO N NA NA N
N N YES NO NO N NA NA >3 DAYS
N N N NO NO N NA NA N
N N YES NO NO N NA NA >3DAYS
N N N NO NO N NA NA N
N N YES NO NO N NA NA <3DAYS
N N N NO NO N NA NA N
N N N NO NO N NA NA N
N N YES NO NO N NA NA <3 DAYS
N N YES NO NO N NA NA >3DAYS
N N YES NO NO N NA NA >3DAYS
N N N NO NO N NA NA N
YES N N NO NO N NA NA N
N N YES NO NO N NA NA N
N N N NO NO N NA <3 DAYS N
N N YES NO NO N NA NA <3 DAYS
N N N NO NO N NA NA N
N N YES NO NO YES NA NA N
N N YES NO NO N <3DAYS NA N
N YES N NO NO N NA >3 DAYS N
N N N NO NO N NA NA N
N N YES NO NO N NA NA >3 DAYS
N N YES NO NO N NA NA >3DAYS
N N YES NO NO N <3 DAYS NA <3 DAYS
N YES N NO NO N NA NA N
YES N YES NO NO N NA >3 DAYS N
N N N NO NO N NA NA N
N N N NO NO N NA NA N
N N N NO NO N NA >3 DAYS N
N N YES NO NO N NA NA N
N N N NO NO N NA NA N
N N N NO NO N NA NA N
N YES YES NO NO N NA NA <3 DAYS
N YES YES NO NO N NA NA >3DAYS
91
N N YES NO NO N NA >3 DAYS N
N N N NO NO N NA NA N
N N N NO NO N NA NA N
N N YES NO NO N NA NA >3 DAYS
Apgar
Gr1
Apgar
Gr2
Apgar
Gr3 MB gr1 MBgr2 MB Gr3
Nndeath
1 NNdeath2 NNdeath3
7 8 7 NO NO NO NO NO no
8 7 7 NO NO NO NO NO no
9 7 7 NO NO NO NO NO no
8 8 5 NO NO YES(P.edema,AKI) NO NO no
6 8 NA NO NO yes(ab) NO NO non
7 7 7 NO NO no NO NO no
7 8 8 NO NO NO NO NO no
8 7 7 NO NO NO NO NO no
7 7 3 NO NO NO NO NO yes
8 7 8 NO NO NO NO NO no
7 7 7 NO NO NO NO NO no
8 5 6 NO NO NO NO NO no
7 7 6 NO NO YES(ab) NO NO no
8 8 7 NO NO NO NO NO no
7 8 8 NO NO NO NO NO no
8 8 8 NO NO NO NO NO no
8 8 7 NO NO NO NO NO no
7 8 7 NO NO NO NO NO no
7 8 8 NO NO NO NO NO no
7 7 8 NO NO NO NO NO no
3 7 8 NO NO NO NO NO no
8 7 6 NO NO NO NO NO no
7 7 8 NO NO NO NO NO no
7 7 4 NO NO
YES(PPH,P
edema) NO NO yes
7 6 7 NO NO NO NO NO no
5 6 7 NO NO NO NO NO no
8 7 8 NO NO NO NO NO no
7 5 7 NO NO NO NO NO no
8 7 7 NO NO NO NO NO no
7 8 7 NO NO NO NO NO no
8 3 8 NO NO YES NO NO no
7 8 9 NO NO NO NO NO no
8 7 8 NO NO NO NO NO no
7 8 8 NO NO NO NO NO no
7 7 7 NO NO NO NO NO no
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7 7 5 NO NO YES(ab,HELLP NO NO no
8 4 8 NO NO NO NO NO no
8 8 NA NO NO YES(ab,HELLP NO NO no
8 7 9 NO NO NO NO NO no
8 8 6 NO NO NO NO NO no
IUD Gr1 IUD Gr2 IUD Gr3
NO NO N
NO NO N
NO NO N
NO NO N
NO NO YES
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
NO NO N
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NO NO N
NO NO N
NO NO YES
NO NO N
NO NO N
